THE BEST SIDE OF JOURNAL OF ARTHRITIS AND RHEUMATOLOGY

Journal of Arthritis and RheumatologyJournal of Arthritis and RheumatologyJournal of Arthritis and RheumatologyA randomized, double-blind, placebo managed, period III scientific demo evaluated the efficacy and security profile of adalimumab being a monotherapy in sufferers with RA who had failed to reply to csDMARDs [191]. The outcome confirmed the